Important Safety Information Prescribing Information Patient Site

Training

Best Practices for YCANTH administration

Photo is illustrative and not representative of all patients.

Please review all 10 steps of the YCANTH Instructions for Use (IFU).

DOWNLOAD YCANTH IFU

The IFU must always be followed as the primary resource for guidance on use of the YCANTH applicator. Below are additional best practices for preparing the YCANTH applicator for treatment.

Tap the YCANTH applicator

Gently Tap the YCANTH applicator to move the YCANTH solution
(Step 6 of IFU)

Gently tap the capped end of the YCANTH applicator on a horizontal surface for approximately 10 seconds or until the YCANTH solution has collected at the bottom of the applicator tube.

Best-practice tips

  • Only tap if YCANTH solution has not collected at the bottom of the applicator tube
  • Gravity moves the solution to the tip of the applicator
  • Do NOT apply pressure to the applicator tube during this step
  • Do NOT push the drug solution through the filter during this step
  • Invert the applicator (seesaw motion) after EACH lesion is treated to avoid YCANTH on healthy skin
Test the YCANTH applicator

Test the YCANTH applicator (Step 7 of IFU)

Remove the applicator cap. Gently squeeze the applicator tube to apply a droplet to a paper towel or gauze to confirm the YCANTH applicator is working properly.

Best-practice tips

  • Establish the flow of YCANTH solution before dispensing onto a molluscum lesion. The key here is to establish the amount of solution and flow based on finger pressure and angle of the applicator when testing onto the gauze BEFORE the solution is delivered to a lesion
Apply YCANTH solution to lesion

Apply a small droplet of the YCANTH solution onto a molluscum lesion (Step 8 of IFU)

Use the applicator tip to spread the solution to cover the entire lesion.

Best-practice tips

  • Most molluscum lesions are 1 to 5 mm in diameter. The tip of the applicator is 1 mm in diameter and designed to deliver a targeted dose of YCANTH to each lesion. You need very little drug to cover an entire molluscum lesion with a thin film of drug solution. There is no need to spread YCANTH if the lesion is only 1 to 3 mm because that is about the size of a small droplet
Allow YCANTH Solution to completely dry

Allow YCANTH Solution to completely dry, up to 5 minutes. (Step 9 of IFU)

This keeps YCANTH off healthy skin.

Best-practice tips

  • Instruct patient to be still and keep body horizontal while solution is drying.
Allow YCANTH Solution to completely dry

Clustered Lesions and/or Sensitive Skin Areas

Some patients will present with several small, clustered molluscum lesions, and/or lesions in sensitive skin areas, such as the face and armpit.

Best-practice tips

  • In these cases, consider treating select but not all lesions. This will help to prevent multiple blisters coalescing into larger blisters.
  • In the YCANTH clinical trials, all baseline and new treatable lesions were treated. For the first few times treating a patient with YCANTH, consider treating just one or two body regions, or select lesions.
Post Treatment Care

Post-treatment Care Instructions

DOWNLOAD NOW

Post Treatment Care

Instruct patients or caregivers to wash the treated skin area with soap and water 24 hours after treatment. Patients may wash YCANTH off skin sooner if they develop severe blistering, severe pain, or other severe reactions.

Best-practice tips

  • Remind patient/caregiver that blisters and local skin reactions are expected. Blistering is a sign that YCANTH is working to help clear the bumps from the skin.
  • Remind patients or caregivers to not use a washcloth, abrasive material, or vigorous rubbing because this could be painful.
  • Over-the-counter pain relief medicines can be used as needed.
  • Send patient home with YCANTH Post Treatment Care Instructions

Before administering YCANTH, please review the full Prescribing Information.

DOWNLOAD YCANTH PI

Watch this training video to learn how to use the YCANTH applicator in your office

You are about to leave the YCANTHPro.com website by opening a new webpage. The site you are linking to is not controlled by Verrica Pharmaceuticals and we are not responsible for the content presented on that site.

Thank you for visiting YCANTHPro.com.

Leave site

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.

HCP=healthcare professional.